• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method for producing antibiotics of the formula He and CH, which consists in the fact that the strain Streptorayces halstedii ATCC 31812 is cultivated in a nutrient medium containing carbon and nitrogen sources and mineral salts, in deep aerobic conditions, followed by separation of the target product from the culture fluid and, if necessary, by transferring it in cationic salt. (L with
    公开号:SU1151219A3
    申请号:SU823464034
    申请日:1982-07-14
    公开日:1985-04-15
    发明作者:Даниель Келмер Вальтер；Патрик Куллен Вальтер；Сибакава Ритиро；Тоне Дзюнсуке
    申请人:Пфайзер,Инк (Фирма)；
    IPC主号:
    专利说明:

    : l
    Nd: o
    This invention relates to the microbiological industry and relates to the preparation of a novel acidic polyester antibiotic.
    No analogs were found in the patent and scientific literature; Ensn CH, the strain of Streptomyces halstedii ATCC 31812 is cultivated in a nutrient medium containing carbon and nitrogen sources and mineral salts, in the depths of aerobic conditions, followed by the purification of the target product from the culture fluid and, if necessary, its translation into cationic salt. The Streptomyces halstedii microorganism used for carrying out the method was extracted from a soil sample in Japan. It was deposited in the American Culture Collection collection under the number 31812 The Streptomyces halstedii strain ATTS 31812 is characterized by the following features. Culture and morphological prizes. Agar of yeast extract - malt extract - good growth, color from cream to light yellowish, moderately elevated, smooth, hardened to wrinkles, without aerial mycelium; the reverse side is the same as the surface; the soluble pigment is absent; Oat flour agar - moderately grown seryum to brown-gray, from slightly to slightly grown, smooth with small white spots; weak aerial mycelium, white to light saronic; the reverse side is the same as the surface; rastorimy pigment light yellowish. Inorganic salts - starch agar - moderate growth, yellowish brown to brown, liquid, smooth, without aerial mycelium; the reverse side is the same as the surface. soluble pigment is absent, Glycerin is aspartic agar growth from moderate to weak, dull, liquid, smooth with a small amount. The purpose of the invention is to provide a method for producing an antibiotic.
    The goal is achieved by the fact that according to the method of obtaining an antibiotic of the formula with these white spots; weak aerial mycelium; white; the reverse side is the same as the surface; without soluble pigment, Gordon and Smith tyrosine agar mild to moderate growth, colorless to cream, liquid, smooth, without aerial mycelium; the reverse side is the same as the surface; without soluble pigment; Cap-sucrose agar - weak growth, colorless to dull white, liquid, smooth, with small white spots of aerial mycelium; the reverse side is the same as the surface; without soluble pigment, Glucose-aspartic agar of moderate growth, yellowish gray to lavender-serogr, liquid, smooth, but slightly wrinkled near the edge; aerial mycelium light gray; the reverse side is the same as the surface; soluble pigment light yellow, Agar with a calcium salt of malic acid - weak growth, colorless with a dull-white edge, flooded, smooth with small spots of grayish aerial mycelium; the reverse side is the same as the surface; without soluble pigment. Casein agar - moderate growth, light brown, liquid, smooth to slightly roughened, without aerial mycelium; inverse c: toron is the same as surface; without soluble pigment. Agar Bannet - good growth, brown, raised, wrinkled, without aerial mycelium; the reverse side is the same as the surface; soluble pigment is light yellowish. 3 Emerson agar - growth from moderate to good, light yellowish-brown to greenish gray, liquid to pinkish, smooth to slightly coarse or appearing as membrane bowls that are irregularly wrinkled, without aerial mycelium, the reverse side is the same as the surface ; without soluble pigment Nutrient agar - growth from weak to moderate, light yellow liquid, smooth, without aerial mycelium; the reverse side is the same as the surface; no soluble pigment. Gelatin agar - growth moderate light yellowish, liquid, smooth, without aerial mycelium; the reverse side is the same as the surface; without soluble pigment. Starch agar - good growth, creamy, light yellow to light yellowish brown, liquid to slightly higher, smooth, but wrinkled towards the edge, without an AIR mycelium; the reverse side is the same as the surface; without soluble pigment. Potato-carrot agar - moderate growth, creamy (2 sa) with a grayish to dark gray edge, liquid, smooth, aerial mycelium from gray to dark gray; the reverse side is the same as the surface; soluble pigment is missing. Water extract agar - poor growth, colorless to dull white, liquid, smooth, with small white spots of aerial mycelium, the reverse side is the same as the surface; soluble pigment is missing. Physical and biological properties. Melanin is not formed. Hydrogen sulfide does not form. Gelatin thins, Starch hydrolyzes. Nitrate reduces to nitrite, limited growth on Jensen cellulose. There is no growth on Levin and Schoenline pulp. No decomposition on both cellulosic media. Milk does not coagulate, does not peptonize. It does not absorb casein, calcium acid malic acid and tyrosine. On the environment Nonomura uses glucose, arabinose, xylose, poorly absorbs raffinose; Inacitol, mannitol, fructose and framed sucrose 194 does not have time When cultivated on potato agar for 15 days, the mass of spores is gray, the chains of spores are straight, crooked, irregularly bent or wavy, sometimes hooked, from 10 to 3Q spores in each chain, rarely less than 10; bevels oval, from elliptical to rod-shaped, 1-1.8x0.8-0.9 microns, smooth,. Good growth at 21-28 C, can grow at ZU-DZ C,. Example 1, Preparing a sterile medium of the following composition, g / l water: cereose 10; starch 20; yeast extract 5; No. Z UTT (casein enzymatic digestion) 5; dipotassium hydrophosphate 0.5; m sleep flour 5; cobalt chloride 0.002; calcium carbonate 4; pH of 7.2-7.1. The culture from the beveled agar was transferred into a row of 300 ml flasks, each containing 40 ml of sterile medium of the indicated composition, shaken on a rotary shaker at 28-36 ° C for 3-4 days. An aliquot of a growing culture sufficient to provide 2 vol.% Of the inoculum is transferred to 4-liter fermenters, each of which contains 2 liters of sterile medium of the following composition, g / l of water: overdose 10; No. Z amine A (casein enzymatically digested 5; starch 20; yeast extract 5; calcium carbonate 1; cobalt chloride 0.002; Fermentation is carried out with stirring at a rate of 1700 rpm and degree of aeration IV; air / V about; media. minutes, for 3-5 days, the culture liquid is filtered at neutral pH, the filtrate is extracted with methyl isobutyl ketone or n-butanol. The organic phase is separated. The aqueous phase is filtered and the suspension is filtered to remove the suspended material. The solid is suspended in methanol, filtered, and ethanol wh The residue is extracted with the same solvent. The extracts are combined and evaporated in a snack, a viscous oil is obtained. It is suspended in heptane, mixed with silica gel, and flt. pure ethyl acetate. After thin layer chromatography and bioanalysis of the fractions, the active fractions are evaporated in vacuo and the residue is rechromatographed to obtain antibiotic 53607 as a solid of the company. Infrared spectrum (tablet with KBG), micron: 2.95; 3.42 j 6.00; 6.37; 6.85; 7.1A; 7.30; 7.65; 7.90; 8.1.9.0 9.15; 9.67; 10.0; 10.18; 10.53; 11.1 11.40; 11.75; 13.25. The antibiotic is soluble in chloroform, ethyl acetate, methyl alcohol, and methyl isobutyl ketone; not soluble in water. Example 2. The inoculum is prepared as in Example 1, but using 700 ml of medium in each flask, the inoculum is fermented in a shaking flask for 3-A days, mixed in two bottles with side branches. A fermenter with a capacity of 6435 l, containing 4542 l of sterile medium, as indicated below, is inoculated with 6 l (0.1%) of the indicated inoculant. Enzyme medium, g / l: cereose 1.0; casein 5.0; starch 5.0; calcium carbonate 3.0; cobalt chloride 0.002; liquid after soaking corn 5.0 ml; water up to 1 l pH 6.9-7.0. Fermentation is carried out at 28 ° C with aeration and stirring at a speed of 1700 rpm. After 120 hours, the farms are unloaded. The entire broth is extracted with 946 l of methyl isobutyl ketone, the layers of the phases are separated in a Podbeln extractor and the organic phase is concentrated in vacuo to give 30.3 l of oil. The oil is further concentrated in vacuo on a rotary evaporator. Residual syrup. Suspended in heptane, mixed with silica gel and filtered, washed several times with heptane. The washed filter residue is treated as in Example 1, to obtain 300 g of oil, which is dissolved in a small amount of chloroform, the solution is poured onto a filter (Lapp) containing 3.5 kg of silica gel, and the silica gel layer is successively washed in 19 l portions of chloroform ethyl acetate and acetone. Fractions were examined by thin layer chromatography. The product was found to be almost completely contained in the ethyl acetate fraction. The other fractions were discarded, the ethyl acetate fraction was evaporated to dryness in vacuo to give 150 g of concentrate. The concentrate is further purified by chromatography on a 8.0x1000 cm column, filled with the same silica gel, to a suspension in ethyl acetate. The column was eluted with ethyl acetate, collecting the liter fractions at a rate of 60 ml / min. The fractions containing product were collected and evaporated in vacuo to give 85 g of product. This product is passed through a column containing 1 kg of Sephadex El-H-20 resin, eluted with methanol at a rate of 25 ml / min. 300 ml fractions are collected. The fractions containing the product were combined and the solvent was evaporated, yielding 30 g of a solid, which was dissolved in 500 ml of chloroform, the solution was washed with an equal volume of 5% sodium dihydrogen phosphate buffer, which was adjusted to pH 4.5 by adding 85% phosphoric acid. The organic layer is separated, washed with 500 ml of 5% disodium hydrogen phosphate buffer, which is adjusted to pH 9.0 by addition of 1N. sodium hydroxide solution. The extract is then dried over anhydrous sodium sulphate and evaporated to dryness in vacuo. The solid residue is dissolved in acetone and allowed to crystallize in the refrigerator. The crystals are collected by filtration and dried under high vacuum at room temperature, yielding 14 g of sodium salt of antibiotic 53607 with T.Sh1. 199-204 ° C. Optical rotation: (o () (, in chloroform), (c) d437 (, in methanol). UV-a ptr: A MO KS 233 nm (in methanol, E, 7 212). Infrared spectrum (tablet with KBr ) μm: 2.95; 3.42; b, 00; 6.37; 6.85; 7.14; 7.30; 7.65; 7.90; 8.10; 9.05; 9, 15; 9.67; 10.00; 10.18; 10.53; 11.15; And, 40; 11.75; 13.25. Elemental analysis: C 57.54; H7.74, N 0.0 Use buffer solutions, (pH 4.5) and CrHP04, adjusted to pH 9.0 with 1N hydroxide solution.
    potassium, according to this method, the potassium salt of the antibiotic compound 53607 is obtained in the same way (the ammonium salt is obtained in the same way using ammonium dihydrogen phosphate and diammonium hydrogen phosphate in this procedure).
    A portion of the obtained sodium salt of the antibiotic compound 53607 was dissolved in ethyl acetate, water was added and the aqueous phase was adjusted to pH 4.5, its acid was phosphoric acid. The organic layer was separated, dried with sodium sulfate and evaporated in vacuo to give 53607 as a free acids with so pl. 84-95 C.
    Elemental analysis data are obtained for a sample dried overnight in high vacuum at room temperature: C 64.69; H 8.91; N 0.0
    It was found that this acid does not dissolve in water; soluble in chloroform, ethyl acetate, methanol and methyl isobutyl ketone
    (“I) jj + 74.5 (, in chloroform) ,.
    (oi) jj + 49.7 (, in methanol).
    UV spectrum: j, j, j 233 nm (in methanol, E ;;;; 198).
    IR spectrum (tablet with KBG), micron: 2.95; 3.45; 6.00; 6.85; 7.28; 8.13; 9.05; 9.67; 10.20; 10.55; 11.15; 11.48.
    The barium salt is obtained by shaking 2.0 g of the free acid, dissolved in 80 ml of ethyl acetate, with an equal volume of water containing 2.4 g of barium hydroxide octahydrate. Separate the layers, wash the organic phase with a fresh solution of barium hydroxide octahydrate, dry with sodium sulfate and evaporate in vacuo to obtain the antibiotic 53607 compound salt.
    Calcium salt (prepared according to this procedure), but using calcium hydroxide instead of barium hydroxide octahydrate.
    Example 4. According to the method of Example 1, a 4% inoculum solution in 4-liter fermentors is used, each of which contains 2 liters of the following sterile medium, g / l: cerelose 10; corn starch 10} soybean powder 10; calcium carbonate 1; corn fermentable solid 5; sodium chloride 5; pH 7.0
    Fermentation is carried out for 2 days at 36 ° C and stirring at a speed of 1700 rpm while purging with air at a speed of 2 rev / v of broth / / min. The whole broth is extracted with chloroform and treated in tio to example 1, to obtain the compound of antibiotic 53607 as a mixture of its sodium, potassium and calcium salts.
    . When this procedure is repeated, but instead of cereose, glycerin is used in the fermentation medium, as well as fish meal or flour from cotton seeds instead of fermented corn solid matter and fermented at pH 8.0, for 6 days, almost the same results.
    权利要求:
    Claims (1)
    [1]
    The METHOD FOR PRODUCING AN ANTIBIOTIC formula is that the strain Streptomyces halstedii ATCC 31812 is cultivated in a nutrient medium containing carbon and nitrogen sources and mineral salts, under deep aerobic conditions, followed by isolation of the target product from the culture fluid and, if necessary, transferring it to a cationic salt. ~ (L
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1151219A3|1985-04-15|Method of obtaining antibiotic
    US4226941A|1980-10-07|Process for the optical resolution of d,l-2-amino-4-methylphosphinobutyric acid
    GB2031896A|1980-04-30|A process for the optical resolution of D,L-2-amino-4- methylphosphinobutyric acid
    CA2008147A1|1990-07-20|Antibiotic l53-18a and process for preparation thereof
    KR920009510B1|1992-10-17|Process for manufacturing lankacidins
    US3950514A|1976-04-13|Antibiotic TM-481 derived from microorganism of the streptomyces ribosidificus group
    US3914158A|1975-10-21|Antibiotic production
    US3974035A|1976-08-10|Process for preparing a cephamycin type antibiotic substance
    US4927810A|1990-05-22|Efomycin G and it's use as yield promoter in animals
    DK143570B|1981-09-07|METHOD OF PREPARING MAYTANSINOL MAYTANACIN AND OR MAYTANSINOL PROPIONATE
    SU1296009A3|1987-03-07|Micromonospora sp.nrrl 15118 starin - producer of producer of antibiotic complex and method for producing antibiotic complex
    JP3107455B2|2000-11-06|New antibiotic MI481-42F4-A and method for producing the same
    EP0414914A1|1991-03-06|New substance trehalostatin and production thereof
    US2972569A|1961-02-21|Hortesin, an antifungal agent derived from streptomyces versipellis
    US4588822A|1986-05-13|Physiologically active substances SS 12538, their preparation and a novel microorganism producing same
    SU1296010A3|1987-03-07|Method for producing 19-epidianemycin and atcc 39205 strain used for producing 19-epidianemycin
    US4940582A|1990-07-10|Antibiotic YI-HU3
    US4202886A|1980-05-13|Antibiotic SF-1942 substance and process for production of the same
    JP2966859B2|1999-10-25|Novel bioactive substance dioctatin and method for producing the same
    JP2592468B2|1997-03-19|Benanomycins A and B, novel antibiotics and their production
    HU179912B|1982-12-28|Process for producing polyether antibiotics
    US4661352A|1987-04-28|WS 7739 substances, their preparation and pharmaceutical composition containing the same
    SU518142A3|1976-06-15|The method of obtaining 7 | -methoxy-psulfooxycinnamoyloxymethyl) 7-methoxy-3-cephem-4-carboxylic acid and 7- | methoxy-p-hydroxycinamoyloxymethyl) -7-methoxy-3-cephem-4-carboxylic acid
    EP0074849A1|1983-03-23|A-32724 antibiotics and process for production thereof
    JP3067322B2|2000-07-17|Method for producing 3'-hydroxybenanomycin A, an antifungal antibiotic
    同族专利:
    公开号 | 公开日
    IN158870B|1987-02-07|
    FI71950B|1986-11-28|
    PL237567A1|1983-03-14|
    IE53265B1|1988-09-28|
    HU189600B|1986-07-28|
    DK158746C|1990-12-03|
    PT75268B|1985-12-13|
    CA1182414A|1985-02-12|
    ES8308360A1|1983-08-16|
    US4361649A|1982-11-30|
    YU155982A|1984-12-31|
    PL130945B1|1984-09-29|
    JPS6248671B2|1987-10-15|
    GR77226B|1984-09-11|
    YU42781B|1988-12-31|
    ZW12582A1|1982-09-18|
    DK323482A|1983-01-21|
    MX7192E|1987-12-23|
    FI822544A0|1982-07-19|
    DK158746B|1990-07-09|
    DD208990A5|1984-04-18|
    NO156653C|1987-10-28|
    JPS5859987A|1983-04-09|
    AU533091B2|1983-10-27|
    DE3266931D1|1985-11-21|
    AT16107T|1985-11-15|
    KR840000642A|1984-02-25|
    CS229936B2|1984-07-16|
    AU8615582A|1983-02-03|
    ZA825129B|1983-05-25|
    NZ201314A|1984-10-19|
    AR227730A1|1982-11-30|
    FI71950C|1987-03-09|
    NO822480L|1983-01-21|
    PT75268A|1982-08-01|
    EP0070669B1|1985-10-16|
    FI822544L|1983-01-21|
    KR860000217B1|1986-03-15|
    EP0070669A1|1983-01-26|
    PH17606A|1984-10-05|
    ES514141A0|1983-08-16|
    NO156653B|1987-07-20|
    IE821720L|1983-01-20|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2771392A|1953-04-06|1956-11-20|Pfizer & Co C|Carbomycin complexes|
    US2991230A|1959-06-24|1961-07-04|Pfizer & Co C|Oxygenation of steroids with streptomyces halstedii|
    US4022885A|1975-02-10|1977-05-10|Pfizer Inc.|Polycyclic ether antibiotic|
    FR2408619B1|1977-10-07|1980-04-04|Rhone Poulenc Ind|
    US4283493A|1978-09-22|1981-08-11|Hoffmann-La Roche Inc.|Process of producing antibiotic X-14766A by a streptomyces|
    JPS5592387A|1978-12-29|1980-07-12|Taisho Pharmaceut Co Ltd|Antibiotic substance tm-531|
    JPS6412277B2|1980-09-27|1989-02-28|Taisho Pharma Co Ltd|US4510317A|1983-07-28|1985-04-09|Hoffmann-La Roche Inc.|Antibiotic X-14934A|
    US4552843A|1984-02-17|1985-11-12|Pfizer Inc.|Process for producing an acidic polycyclic ether antibiotic by cultivation of a novel strain of Streptomyces endus subspecies aureus|
    US4625041A|1984-02-17|1986-11-25|Pfizer Inc.|Acidic polycyclic ether antibiotic|
    US5275938A|1984-03-09|1994-01-04|Nisshin Flour Milling Co., Ltd.|Process for producing leucanicidin|
    FR2570378B1|1984-09-19|1987-05-22|Sanofi Sa|NOVEL POLYETHER IONOPHORE, PROCESS FOR OBTAINING SAME, AND VETERINARY FOOD OR THERAPEUTIC COMPOSITIONS CONTAINING THE SAME|
    IN166452B|1985-04-09|1990-05-12|Pfizer|
    US5665542A|1989-11-03|1997-09-09|Research Institute Of Palo Alto Medical Foundation|Toxoplasma gondii P28 gene and methods for its use|
    WO2017163022A1|2016-03-23|2017-09-28|Parker Hannifin Manufacturing Limited|An adsorption drying unit|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/285,264|US4361649A|1981-07-20|1981-07-20|Polycyclic ether antibiotic|
    [返回顶部]